Holen Sie sich die Stockscreener-App
1.145
2.70%
0.035
Schlusskurs vom Vortag:
$1.11
Offen:
$1.128
24-Stunden-Volumen:
2.38M
Relative Volume:
0.44
Marktkapitalisierung:
$214.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-1.0701
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
-12.98%
1M Leistung:
-2.56%
6M Leistung:
-51.69%
1J Leistung:
-67.05%
1-Tages-Spanne:
$1.12
$1.16
1-Wochen-Bereich:
$1.0601
$1.30
52-Wochen-Spanne:
$1.0601
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.145 | 207.87M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.80 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.71 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.75 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
861.56 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.47 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Eingeleitet | Barclays | Overweight |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - Bölüm Sonu Canavarı
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Is Humacyte Inc. Equity Warrant stock a contrarian buy2025 Breakouts & Breakdowns & Safe Capital Growth Plans - DonanımHaber
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - Улправда
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Humacyte secures up to $77.5 million credit facility with Avenue Capital - Investing.com Nigeria
Humacyte secures $77.5 million loan facility - MSN
Humacyte announces credit facility of up to $77.5 million with Avenue Capital - marketscreener.com
Humacyte Signs $77.5 Million Credit Facility - marketscreener.com
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives - Quiver Quantitative
Humacyte, Inc. Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Humacyte Terminates Revenue Interest Agreement - The Globe and Mail
Total debt per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView — Track All Markets
Humacyte Secures $77.5 Million Loan Facility - TipRanks
[8-K] Humacyte, Inc. Reports Material Event | HUMA SEC FilingForm 8-K - Stock Titan
Humacyte terminates revenue interest purchase agreement - marketscreener.com
Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold" - MarketBeat
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte Stock (HUMA) Opinions on FDA Approval for Symvess Product - Quiver Quantitative
Humacyte (HUMA): Benchmark Remains Bullish on Stock - Finviz
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Humacyte prices 28.4M shares at $2.11 in registered direct offering - MSN
Market Moves: Can Humacyte Inc stock weather global recessionPortfolio Risk Report & Reliable Intraday Trade Plans - moha.gov.vn
Bond Watch: Will Humacyte Inc Equity Warrant stock pay special dividendsJuly 2025 Volume & Low Volatility Stock Recommendations - BỘ NỘI VỤ
Book value per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? - Finviz
How Humacyte Inc. Equity Warrant stock reacts to global recession fearsBuy Signal & High Accuracy Buy Signal Tips - Newser
Can Humacyte Inc. stock continue upward trendPortfolio Growth Summary & Momentum Based Trading Signals - Newser
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Humacyte, Inc.'s (NASDAQ:HUMA) largest shareholders are retail investors with 57% ownership, institutions own 26% - Yahoo Finance
Will Humacyte Inc. stock maintain growth storyForecast Cut & High Accuracy Trade Alerts - Newser
Can Humacyte Inc. stock maintain growth trajectoryMarket Volume Summary & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Humacyte (HUMA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Humacyte stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
What drives Humacyte Inc stock priceGap Up/Gap Down Analysis & Collaborate and Win Together - earlytimes.in
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - MSN
Humacyte (HUMA) Q3 2025 Earnings Call Transcript - The Globe and Mail
Humacyte Ends Sale Agreement with Jefferies LLC - MSN
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):